FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Phillies All Star Talks Sports & Stocks
- Lightning Round: Huntington Bancshares, Emerson Electric, NetApp and More
- Lightning Round OT: Sociedad Quimica and More
- Cramer Speculates on Cyber Crime
- Insana Defends His Call
- Cramer: Wall Street Ennui Is Your Opportunity
- Cramer: Cancel GM, AIG Trading
- Was Chattem's Quarter Good Enough?
- Lightning Round: Delta, Best Buy, Sunoco and More
- Lightning Round OT: Chevron, Joy Global and More


Cramer was blunt in how he feels after recommending Nastech Pharmaceutical [NSTK
Loading...
()
] after speaking with the company’s CEO last week: “I want to bash myself in the head for Nastech,” he said on Wednesday’s show.
The stock lost nearly 40% of its value on Wednesday’s open after news surfaced that Procter & Gamble [PG
Loading...
()
] had terminated a partnership with Nastech on a nasal spray used to treat osteoporosis. Quay had expressed confidence about the deal with Procter when he was on the show last week.
P&G is one of the best companies in America, as far as Cramer is concerned. He’s not sure why investors would want to be involved with a company that makes a drug that P&G rejected.
Appearing on Mad Money again, Dr. Stephen Quay, CEO of Nastech, told Cramer it appeared P&G broke out of its partnership because Nastech wasn’t able to achieve the dosage it wanted. Quay called it a “timing issue,” saying his company will continue to do trials on the nasal spray at higher doses and phase II data on the drug, as well as Nastech’s other insulin and obesity drugs, is expected next year.
The bottom line? No one ever made a dime panicking, as Cramer likes to say. The jury is still out on NSTK down over $5. Cramer took responsibility for calling the stock a buy just last week. “Someone screwed up,” he said. “I’ll take the blame."
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?




